Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) was upgraded by investment analysts at Raymond James to a “moderate buy” rating in a report issued on Thursday,Zacks.com reports.
Other equities analysts have also issued reports about the company. Jefferies Financial Group reissued a “hold” rating and issued a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. DA Davidson reaffirmed a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a research report on Monday, December 9th. Finally, StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $85.25.
View Our Latest Stock Analysis on PBH
Prestige Consumer Healthcare Trading Up 0.1 %
Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. During the same quarter in the prior year, the firm posted $1.07 earnings per share. The business’s quarterly revenue was down .9% compared to the same quarter last year. Equities analysts expect that Prestige Consumer Healthcare will post 4.44 earnings per share for the current year.
Insider Buying and Selling at Prestige Consumer Healthcare
In related news, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now directly owns 320,952 shares in the company, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the sale, the executive vice president now directly owns 18,365 shares in the company, valued at $1,505,930. The trade was a 33.04 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,810 shares of company stock valued at $3,187,300. Company insiders own 1.60% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in PBH. Lombard Odier Asset Management USA Corp bought a new position in shares of Prestige Consumer Healthcare in the second quarter worth $550,000. Sequoia Financial Advisors LLC grew its position in Prestige Consumer Healthcare by 12.9% during the third quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company’s stock worth $708,000 after buying an additional 1,120 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Prestige Consumer Healthcare by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock valued at $95,678,000 after acquiring an additional 50,961 shares in the last quarter. Pinnacle Associates Ltd. boosted its position in shares of Prestige Consumer Healthcare by 60.3% during the 3rd quarter. Pinnacle Associates Ltd. now owns 24,630 shares of the company’s stock valued at $1,776,000 after acquiring an additional 9,269 shares during the last quarter. Finally, Ariel Investments LLC grew its holdings in shares of Prestige Consumer Healthcare by 10.7% during the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock worth $195,204,000 after purchasing an additional 274,212 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.
Prestige Consumer Healthcare Company Profile
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Further Reading
- Five stocks we like better than Prestige Consumer Healthcare
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- What Are Trending Stocks? Trending Stocks Explained
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- Business Services Stocks Investing
- MarketBeat Week in Review – 12/16 – 12/20
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.